.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX08_Mitiglinide.Mitiglinide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX08_Mitiglinide.Mitiglinide| name: | Mitiglinide |
| ATC code: | A10BX08 | route: | oral |
| n-compartments | 1 |
Mitiglinide is a rapid-acting insulin secretagogue of the meglitinide class that stimulates insulin release from pancreatic beta cells. It is used primarily for the treatment of type 2 diabetes mellitus, particularly in Japan and certain Asian countries. It is not widely approved in the United States or Europe.
Pharmacokinetic parameters following a single 10 mg oral dose in healthy adult male volunteers.
Liu, S, et al., & Ju, W (2017). Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers. BMC pharmacology & toxicology 18(1) 54–None. DOI:10.1186/s40360-017-0161-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28676080
Zhang, J, et al., & Zhang, QZ (2012). The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. Journal of clinical pharmacy and therapeutics 37(1) 95–99. DOI:10.1111/j.1365-2710.2011.01257.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21517925
Kadokura, T, et al., & Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clinical pharmacokinetics 53(11) 975–988. DOI:10.1007/s40262-014-0180-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/25316572